Drug Trial Radar · NCT06987851
An Extension Clinical Study of the Efficacy and Safety of BCD-132 in Patients With Multiple Sclerosis Who Previously Received Therapy in Clinical Studies of JSC BIOCAD
Last checked: Nov 19, 2026Latest source record: May 23, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
44
Actual
Start
Mar 22, 2022
Primary completion
May 16, 2024
Study completion May 16, 2024
Sponsor
- Lead sponsor
- BiocadIndustry
- Sponsor type
- Industry
- First posted
- May 23, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The aim of this clinical study is to assess the long-term efficacy and safety of BCD-132 (divozilimab) in patients with multiple sclerosis who previously participaded in BCD-132-2 and BCD-132-4/MIRANTIBUS studies
Conditions
- Multiple Sclerosis
Interventions
DivozilimabBiological
Intravenous infusion of BCD-132 every 24 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Annualized relapse rateTime frame: 48 and 96 weeks
Locations
15 sites in 1 country. Site status is shown where the registry gives one.
Vyacheslav Andreyevich Dudin
Kirov, Russia
Dmitry Vladimirovich Pokhabov
Krasnoyarsk, Russia
Ivan Aleksandrovich Shchukin
Moscow, Russia
Sergey Viktorovich Kotov
Moscow, Russia
Elena Vladimirovna Parshina
Nizhny Novgorod, Russia
Irina Aleksandrovna Sokolova
Nizhny Novgorod, Russia
Gennady Nikolayevich Mishin
Pyatigorsk, Russia
Yuri Vladimirovich Trinitatsky
Rostov-on-Don, Russia
Zoya Aleksandrovna Goncharova
Rostov-on-Don, Russia
Leonid Grigoryevich Zaslavsky
Saint Petersburg, Russia
Natalya Agafonovna Totolyan
Saint Petersburg, Russia
Irina Yevgenyevna Poverennova
Samara, Russia
Valentina Mikhaylovna Alifirova
Tomsk, Russia
Stella Anatolyevna Sivertseva
Tyumen, Russia
Irina Vladimirovna Greshnova
Ulyanovsk, Russia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.